Valuation: ReShape Lifesciences

Market Cap 13.55M 12.08M 11.26M 10.25M 19.29M 1.3B 19.44M 136M 52.93M 666M 50.85M 49.75M 2.14B P/E 2026 *
-2.97x
P/E 2027 * -2.42x
Enterprise Value 13.55M 12.08M 11.26M 10.25M 19.29M 1.3B 19.44M 136M 52.93M 666M 50.85M 49.75M 2.14B EV / Sales 2026 *
132x
EV / Sales 2027 * 67.7x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 103K 91.89K 85.61K 77.9K 147K 9.92M 148K 1.03M 402K 5.06M 387K 378K 16.27M 200K 178K 166K 151K 285K 19.26M 287K 2.01M 781K 9.83M 751K 735K 31.6M
Net income -4.49M -4M -3.73M -3.4M -6.39M -432M -6.44M -45.08M -17.54M -221M -16.85M -16.49M -709M -7.85M -7M -6.52M -5.93M -11.18M -756M -11.26M -78.79M -30.66M -386M -29.45M -28.82M -1.24B
Net Debt - -
Logo ReShape Lifesciences
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-